Marshall Wace, LLP Procept Bio Robotics Corp Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 4,147 shares of PRCT stock, worth $142,573. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,147
Previous 114,822
96.39%
Holding current value
$142,573
Previous $6.69 Million
96.44%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding PRCT
# of Institutions
289Shares Held
45.3MCall Options Held
236KPut Options Held
91.9K-
Vanguard Group Inc Valley Forge, PA5.25MShares$180 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$120 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.16MShares$74.2 Million0.04% of portfolio
-
Chicago Capital, LLC1.57MShares$53.9 Million1.39% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.53MShares$52.5 Million0.06% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $1.53B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...